Delivery Order SPE2DB25D3005-SPE2DB26FQBDK
- Not listed
- The Defense Logistics Agency awarded a $3,414.57 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of October 28, 2025. This non-set-aside competitive award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a $1,562.93 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of June 3, 2025. This non-set-aside contract represents a routine pharmaceutical procurement to support federal medical supply requirements. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $26,739.67 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, issued on September 9, 2025, with an ultimate completion date of September 10, 2025, utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award status. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical supply...
- The Defense Logistics Agency awarded a $1,827.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a completion date of September 15, 2025. This non-set-aside contract was competitively awarded on September 12, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,374.24 for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on August 22, 2025, with completion scheduled for August 25, 2025. This firm fixed-price contract represents a non-competitive, direct award to the vendor for pharmaceutical supply fulfillment. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor and healthcare solutions provider for...
- The Defense Logistics Agency awarded a $4,290.28 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of October 30, 2025. This non-set-aside competitive award represents a single delivery order transaction under AmerisourceBergen's existing contract vehicle with DLA. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $1,456.92 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of September 8, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing for the pharmaceutical product, which will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $1,150.32. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025, and represents a non-set-aside competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly...
- The Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $5,751.48 for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order represents a competitive, non-set-aside award to supply pharmaceutical products supporting federal military and veteran healthcare systems. The work will be performed at AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $1,054.35 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of April 22, 2025. This competitive, non-set-aside award reflects the agency's procurement of critical pharmaceutical supplies for military and federal healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a key vendor for...
- SPE2DB25D3005Indefinite Delivery Contract
- SPE2DB25D3005-SPE2DB26FQBDKDelivery Order
The Defense Logistics Agency awarded a $5,390.98 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on November 10, 2025, with completion scheduled for November 12, 2025. This non-set-aside contract represents a small-value pharmaceutical delivery supporting military healthcare supply requirements. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal vendor specializing in medical procurement for defense and veteran healthcare systems. This delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support military healthcare programs worldwide. The arrangement reflects DLA's strategy of maintaining prime vendor relationships with capable distributors to ensure reliable pharmaceutical availability for Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.4k | 11/10/25 |